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RE S P O N S E :  IMPLEMENTING MOTIVATIONAL STEPPED CARE 
Tom Brewster, L.C.S.W., Chris Farentinos, M.D., and Douglas Ziedonis, M.D. 
The methadone 
population has 
changed. Today 
we are treating 
a jobless, skill-
less population 
more difficult 
to treat than 
the patients of 
decades past. 
The changing methadone population 
Chris Farentinos: The methadone population has 
changed. Today we are treating a jobless, skill-less pop-
ulation that is much more difficult to treat than the 
patients of decades past. Still, I am not sure I really see 
any difference in the effectiveness of methadone today 
compared to 10 years ago. I think you have one-third 
of people who will benefit, stay on methadone, get 
good results, improve their life conditions, get a job. 
You have a middle third who will have some relapses 
and will struggle, and might diminish the rate of crim-
inal offenses related to drug-seeking. Then you have 
the bottom third who cycle through programs. 
Doug Ziedonis: The field of addiction has more com-
plicated patients now than in the past, because some 
of the easier patients got treatment and moved for-
ward. In the 1980s, when the 28-day programs started, 
their success rate was phenomenal, probably because 
lots of people got into treatment who should have been 
treated as outpatients. The methadone programs that 
are left get all the really tough cases: dually diagnosed, 
polydrug, polylife problems. Methadone programs 
always get all the toughest cases. 
Juice alone will work for some people, but not 
for tougher cases. So what are you going to do for that 
group? How do we strengthen the social treatment in 
these different places? Part of it is bringing over mod-
els from other settings, as Brooner and Kidorf
have done. 
What community programs can gain from 
the MSC model 
Ziedonis: Having behavioral contracts in methadone 
treatment isn’t a new thing, even in outpatient set-
tings. The big issue is always, what are the consequences 
going to be? Are we going to discharge patients if they 
take drugs? Are we going to push them to a high level 
of care? Do we have a high level care that they can 
go to? Are we going to make them go to more NA 
meetings in the community? 
Brooner and Kidorf ’s paper is good because here 
is one program spelling out the way it thinks about 
these issues. Some of the smaller programs that 
don’t have big psychosocial treatment components 
still have behavioral plans, but theirs don’t offer as 
many benefits, such as an IOP [intensive outpatient 
program] for patients who are doing well as inpatients. 
They are more limited on what positive perks there 
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can be and usually only have negative consequences. 
And, from my experience, they usually are not rigor-
ous in kicking out people who use drugs. 
Farentinos: The strength of the approach described in 
this article is that if you are a patient, your incen-
tives are very strongly connected to attendance and 
changing your behavior. Best of all, the model can 
be translated to pretty much any other program. 
Let me share what we do in an IOP with respect 
to punishment versus increased dosage. This is not a 
methadone program. One of the things we have found— 
and it reflects exactly what the article is saying—is that 
if someone is failing in IOP, turning in drug-positive 
urines and decreasing attendance, policies are effec-
tive that say, so many missed sessions and you are going 
to be bumped up to a more intensive phase, or if you 
have a positive urinalysis, you’ll get bumped up to the 
more intensive phase. If you produce a drug-free urine 
specimen, then you go down again. Having very clear 
benchmarks of progress gives the client a measure of 
control. It emphasizes the whole idea of motivational 
interviewing, in the sense of giving control by laying 
out the rules and consequences very clearly. I think 
that is very smart. 
I met with my IOP people the day after reading 
this article, and a number of things came up because 
of the article. Many counselors have ideas about 
how we can use this structure to make our program 
better. At present we have people pay when they miss 
sessions, whether they are full-pay clients or even if 
they are paying reduced fees. They pay half of the 
charge for each session they miss, which is punitive, 
but it also encourages them to show up. Now we are 
thinking of incorporating an even more structured 
way to quantify steps and increase the client’s control 
over whether he or she goes forward or backward. 
One of the criticisms of voucher programs is the 
cost. With this MSC model, you have some imple-
mentation cost, training cost, and design cost, but you 
don’t have the actual cost of vouchers. I think the MSC 
program design is thought through very well. 
Tom Brewster: I am looking forward to presenting this 
article to my staff. The discussion will be: What do we 
do that is similar to this? How could we modify it to 
use some of these ideas? 
Frankly, I think we will make some changes. 
Specifically, I think we’ll want to quantify our steps 
more clearly than we do right now. Currently we make 
contingencies that involve take-home privileges, maybe 
an increase in counseling sessions, sometimes maybe 
even an adjustment of fees. If you start having posi-
tive urinalyses, your fees will be adjusted upward, so 
you’re better off not having positive urinalyses. I think 
our contingency system as it stands is a little unsys-
tematic. Using Brooner and Kidorf ’s approach would 
clarify things for our staff. It would be standardized. 
Acceptability of the MSC incentives to com-
munity programs and their patients 
Brewster: From a harm-reduction standpoint, in our 
program we don’t like to discharge patients for non-
compliance. The risk of discharging patients from 
methadone programs is that they will inject drugs, 
which makes them vulnerable to HIV, hepatitis, and 
other diseases. Of course, if somebody pulls a gun in 
a clinic or makes threats, they are discharged. But 
for the most part, noncompliance with counseling ses-
sions and what-have-you will not trigger a discharge. 
When a person is noncompliant, this article sug-
gests increasing the dose of treatment. I wouldn’t want 
a patient to feel antagonism toward the counselor asso-
ciated with the allegedly enhanced, almost punitive-
appearing requirements for additional groups or ses-
sions. I would rather have the clinic set certain rules: 
‘Your fee may adjusted; your take-home cycle may be 
adjusted. These are clinic rules and they work the same 
way for everyone.’ 
Ziedonis: Sometimes I use a medical model to explain 
contingencies to a patient. I say, ‘Look, suppose you 
have a broken leg. It could be a simple fracture or a 
compound fracture. In addiction, too, there are vari-
ations in the illness. We are going to get to know you 
and work with you. We are going to start at this level, 
but if a higher level of care is needed, then you will 
have to go to a higher level of care.’ It’s framed, not 
that ‘you did something wrong and then you get this 
consequence,’ but more like ‘we are trying to figure 
out the severity of the illness.’ 
Farentinos: Framing is very important. You can frame 
the thought as, ‘You pay half the fee if you don’t show 
up, because you did a bad thing.’ Or you can frame it, 
‘We really want to see you here. We want to see you 
here so much that the incentive for you to be here is 
not only that you are moving forward faster and not 
being bumped into more intensive levels of care, but 
you also don’t have to pay the extra fee.’& 
Having behav-
ioral contracts 
in methadone 
treatment isn’t
a new thing. 
The big issue is, 
always, what 
are the conse-
quences going 
to be? 
